Cramer said these are just a few stocks that can transcend the macro economies and reward shareholders for years to come.
In the "Executive Decision" segment, Cramer spoke with Paul Palmieri, co-founder, president and CEO of
, an advertising company at the forefront of the Internet's migration to mobile devices.
Palmieri said consumers' transition from desktop to mobile is not necessarily a problem for companies like Millennial that are uniquely mobile. He said that, overall, click-thru rates on mobile ads are higher than their desktop counterparts and advertisers are willing to pay more for them.
Among the differences between desktop and mobile, however, are that on mobile users are likely to begin a transaction from within an app, rather than via a search box. Thus companies like
are able to deliver very precise ads within their own vertical. Since mobile only serves one ad per page, compared to 15 or 16 on a desktop browser, those mobile ads are far more effective.
When asked about Apple's new iPhone, Palmieri said he's excited for a few reasons. First, he said the larger screen means ads can get taller and will be easier to read and click on. Second, 4G speeds mean richer ads with more animations and video. Finally, Apple's Passbook app allows advertisers to "close the loop" and see exactly how many sales are coming from their mobile ad efforts.
Cramer said Millennial remains at the forefront of a great business and he continues to like the stock.
Looking for a Cure
Investors need companies in their portfolios that can transcend politics, Cramer told viewers, and that means companies like those trying to develop treatments for Hepatitis C, the leading cause of liver disease in the U.S. and one that affects over 170 million people worldwide. Cramer said that Hep-C is a $20 billion market opportunity, which is why there are many biotech companies chasing it.
But a lot has happened in the Hep-C race over the past few months, so Cramer laid out the latest news. He said that
, an Action Alerts PLUS holding, was clearly the leader in the space. But after a patient in its clinical trials had a heart attack, its program was halted and later discontinued. Cramer said Bristol-Myers remains a great growth stock with a terrific yield, but it's no longer a player when it comes to Hep-C.